{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:08:12Z","timestamp":1793689692680,"version":"4.5.1"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[1996,10,1]],"date-time":"1996-10-01T00:00:00Z","timestamp":844128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1996,10]]},"abstract":"<jats:p>ER-30346 is a novel oral triazole with a broad spectrum of potent activity against a wide range of fungi. ER-30346, with MICs at which 90% of the strains tested are inhibited (MIC90s) ranging from 0.025 to 0.78 microgram\/ml, was 4 to 32 times more active than itraconazole, fluconazole, and amphotericin B against Candida albicans, Candida parapsilosis, and Candida glabrata. Against Candida tropicalis, ER-30346, with an MIC90 of 12.5 micrograms\/ml, was 2 to &gt; 8 times more active than itraconazole and fluconazole, but was 16 times less active than amphotericin B. ER-30346 (MIC90, 0.78 microgram\/ml) was four to eight times more active than fluconazole and amphotericin B and had activity comparable to that of itraconazole against Trichosporon beigelli. The MIC90s of ER-30346 were 0.10 microgram\/ml for Cryptococcus neoformans and 0.39 microgram\/ml for Aspergillus fumigatus. ER-30346 was 2 to 8 times more active than itraconazole and amphotericin B and 32 to &gt; 256 times more active than fluconazole. ER-30346 also showed good activity against dermatophytes, with MICs ranging from 0.05 to 0.39 microgram\/ml, and its activity was comparable to or 2 to 16 times higher than those of itraconazole and amphotericin B and &gt; 32 times higher than that of fluconazole. In vivo activity was evaluated with systemic infections in mice. Against systemic candidiasis and cryptococcosis, ER-30346 was comparable in efficacy to fluconazole and was more effective than itraconazole. Of the drugs tested, ER-30346 was the most effective drug against systemic aspergillosis. We studied the levels of ER-30346 in mouse plasma. The maximum concentration of drug in plasma and the area under the concentration-time curve for ER-30346 showed good linearity over a range of doses from 2 to 40 mg\/kg of body weight.<\/jats:p>","DOI":"10.1128\/aac.40.10.2237","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:24:09Z","timestamp":1539044649000},"page":"2237-2242","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":95,"title":["In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum"],"prefix":"10.1128","volume":"40","author":[{"given":"K","family":"Hata","sequence":"first","affiliation":[{"name":"Department of Microbiology and Infectious Disease, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Disease, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Disease, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Toyosawa","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Disease, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Disease, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Katsu","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Disease, Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.40.10.2237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.40.10.2237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:04:28Z","timestamp":1645473868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.40.10.2237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,10]]},"references-count":0,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1996,10]]}},"alternative-id":["10.1128\/AAC.40.10.2237"],"URL":"https:\/\/doi.org\/10.1128\/aac.40.10.2237","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,10]]},"assertion":[{"value":"1996-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}